文献速递临床试验与 GCP流行病学与生物统计

利福平单剂化学预防麻风多菌型患者接触者的随机对照试验研究方案

Chemoprophylaxis of leprosy with rifampicin in contacts of multibacillary patients: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-04-23

该研究为IV期随机双盲安慰剂对照试验,评估多菌型麻风患者接触者在接种BCG前接受单剂利福平化学预防能否减少疫苗接种后数月内发病。接触者按2:1随机分为利福平+BCG组与安慰剂+BCG组,随访12个月比较亚临床感染(PCR)及免疫学指标(抗PGL-1、抗LID-1、IFN-γ)。

要点

  • 单剂利福平联合BCG用于多菌型麻风接触者化学预防的IV期随机双盲安慰剂对照试验
  • 主要评估BCG接种前使用利福平能否预防接种后数月内发病
  • 随访12个月比较PCR检测的亚临床感染及抗PGL-1、抗LID-1、IFN-γ等免疫指标

核心结论

  • 旨在评估多菌型麻风患者接触者在BCG接种前接受单剂利福平化学预防能否预防疫苗接种后数月内发生的麻风病例。

研究设计与样本

  • IV期化学预防临床试验,在Souza Araújo门诊/FIOCRUZ管理的多菌型麻风患者接触者中给予单剂利福平。
  • 随机(2:1)、双盲、安慰剂对照研究,分为利福平+BCG组与安慰剂+BCG组。
  • 随访12个月,评估接触者亚临床感染(聚合酶链反应)及免疫学参数(抗PGL-1、抗LID-1、IFN-γ)并比较结果。
  • 试验在巴西临床试验注册平台(ReBEC)注册,编号RBR-69QK5P,2017年6月1日回顾性注册。

关键数值与推荐

  • 接触者随机分组比例为2:1(利福平+BCG组:安慰剂+BCG组)。
  • 化学预防为单剂利福平,在BCG疫苗接种前给予。
  • 随访时间为12个月。
  • 评估指标包括聚合酶链反应检测的亚临床感染及抗PGL-1、抗LID-1、IFN-γ免疫学参数。

临床怎么用

  • 为多菌型麻风患者接触者中单剂利福平联合BCG化学预防策略提供随机对照试验证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The annual new-case detection rate for leprosy, while generally stable over the last decade, shows that transmission rates have remained stagnant despite the successful worldwide administration of multidrug therapy since the 1980s. As such, novel control strategies are urgently needed. Focusing on managing leprosy patient contacts, the most susceptible to contracting the disease, has been seen as a potential strategy in limiting the spread of leprosy as shown by a number of recent epidemiological studies. Immunoprophylaxis with Bacillus Calmette-Guérin (BCG) has been seen as an effective preventive measure due to its ability to stimulate the development of cellular immunity which is essential in controlling the disease, especially in its multibacillary (MB) forms. The association of immunoprophylaxis with chemoprophylaxis in a single dose of rifampicin has been shown to be a promising preventive strategy, although a variety of studies have found instances of early case detection just a few months after BCG vaccination. METHODS/DESIGN: The present study is a phase IV chemoprophylactic clinical trial consisting of administration of a single dose of rifampicin in MB leprosy patient contacts under care at the Souza Araújo Outpatient Clinic/FIOCRUZ as part of a randomized (2:1), double-blind, placebo-controlled study. It is comprised of two groups: 1) rifampicin + BCG; and 2) placebo + BCG. DISCUSSION: The aim is to evaluate whether the use of chemoprophylaxis with a single dose of rifampicin in MB leprosy patient contacts prior to the BCG vaccine would be able to prevent the onset of leprosy in those cases that may occur just a few months after vaccination. Contact subclinical infections (polymerase chain reaction) and the immunological parameters (anti-PGL-1, anti-LID-1, and IFN-γ) will be evaluated and the results will be compared after 12 months of follow-up. TRIAL REGISTRATION: The Brazilian Registry of Clinical Trials (ReBEC), RBR-69QK5P . Retrospectively registered on 1 June 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Dos Santos DS, Duppre NC, Sarno EN, et al. Chemoprophylaxis of leprosy with rifampicin in contacts of multibacillary patients: study protocol for a randomized controlled trial. Trials. 2018. PMID: 29685164. doi:10.1186/s13063-018-2623-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。